Steven Cohen Revolution Medicines, Inc. Transaction History

Point72 Asset Management, L.P.

$36 Billion
Q2 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 227,922 shares of RVMD stock, worth $13.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

227,922

Previous 227,922 -0.0%

Holding current value

$13.8 Million

Previous $8.85 Million -0.0%

% of portfolio

0.02%

Previous 0.02%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$30.14 - $40.68 $6.87 Million - $9.27 Million	227,922 New	227,922 $8.85 Million
Q3 2023 Nov 14, 2023	BUY	$25.17 - $35.05 $6,795 - $9,463	270 New	270 $7,000
Q1 2023 May 15, 2023	SELL	$20.76 - $30.09 $7.96 Million - $11.5 Million	-383,339 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$17.68 - $25.53 $6.78 Million - $9.79 Million	383,339 New	383,339 $9.13 Million
Q2 2022 Aug 15, 2022	SELL	$14.54 - $27.17 $5.3 Million - $9.9 Million	-364,431 Reduced 92.94%	27,667 $539,000
Q1 2022 May 16, 2022	BUY	$17.31 - $26.4 $6.79 Million - $10.4 Million	392,098 New	392,098 $10 Million
Q4 2021 Feb 14, 2022	SELL	$24.35 - $33.7 $1.34 Million - $1.85 Million	-55,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$23.95 - $33.41 $3.3 Million - $4.6 Million	-137,600 Reduced 71.44%	55,000 $1.51 Million
Q2 2021 Aug 16, 2021	BUY	$29.0 - $47.44 $5.59 Million - $9.14 Million	192,600 New	192,600 $6.11 Million

Others Institutions Holding RVMD

# of Institutions

245

Shares Held

160M

Call Options Held

251K

Put Options Held

133K

View Full List

About Revolution Medicines, Inc.

Ticker RVMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,697,600
Market Cap $5.3B
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...

More about RVMD

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account